Celldex Therapeutics (CLDX) Reaches New 12-Month High and Low at $1.98

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares reached a new 52-week high and low during trading on Friday . The stock traded as low as $1.98 and last traded at $1.99, with a volume of 1487928 shares traded. The stock had previously closed at $2.07.

Several research analysts have recently commented on CLDX shares. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, March 7th. HC Wainwright set a $10.00 price objective on Celldex Therapeutics and gave the company a “buy” rating in a research note on Friday, February 9th. Finally, Leerink Swann reiterated a “market perform” rating and issued a $3.00 price objective (down from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, March 8th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Celldex Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $6.38.

How to Become a New Pot Stock Millionaire

The company has a market cap of $292.02, a PE ratio of -2.49 and a beta of 2.45.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. The business had revenue of $3.50 million for the quarter, compared to analysts’ expectations of $1.49 million. Celldex Therapeutics had a negative return on equity of 44.64% and a negative net margin of 730.06%. The company’s revenue for the quarter was up 87.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.30) earnings per share. equities research analysts forecast that Celldex Therapeutics, Inc. will post -0.72 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in CLDX. Cubist Systematic Strategies LLC acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at $101,000. OxFORD Asset Management LLP acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at $122,000. Teacher Retirement System of Texas raised its stake in Celldex Therapeutics by 325.0% in the fourth quarter. Teacher Retirement System of Texas now owns 43,253 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 33,077 shares in the last quarter. MetLife Investment Advisors LLC acquired a new stake in Celldex Therapeutics in the fourth quarter valued at $187,000. Finally, Two Sigma Advisers LP acquired a new stake in Celldex Therapeutics in the fourth quarter valued at $238,000. Institutional investors and hedge funds own 55.49% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Celldex Therapeutics (CLDX) Reaches New 12-Month High and Low at $1.98” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3339944/celldex-therapeutics-cldx-reaches-new-12-month-high-and-low-at-1-98.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

SJW Group  Rating Lowered to Neutral at Janney Montgomery Scott
SJW Group Rating Lowered to Neutral at Janney Montgomery Scott
Boeing  Rating Reiterated by Wells Fargo
Boeing Rating Reiterated by Wells Fargo
Escroco  Market Capitalization Tops $0.00
Escroco Market Capitalization Tops $0.00
Tritax Big Box REIT  Rating Reiterated by Numis Securities
Tritax Big Box REIT Rating Reiterated by Numis Securities
United Microelectronics  Releases  Earnings Results
United Microelectronics Releases Earnings Results
New Gold  Announces  Earnings Results
New Gold Announces Earnings Results


© 2006-2018 Ticker Report. Google+.